RecruitingNCT01650311

Investigating Serotonin Signalling in IBD Patients

Sponsor

McMaster University

Enrollment

60 participants

Start Date

Jul 1, 2012

Study Type

OBSERVATIONAL

Conditions

Inflammatory Bowel Disease

Summary

Alterations in normal serotonin (5-hydroxytryptamine;5-HT) signaling have been reported in ulcerative colitis (UC) and Crohn's disease (CD). Studies report an increase in enterochromaffin (EC) cell, main source of 5-HT in the gut, numbers in CD and UC patients. Up-regulated expression of mucosal Tryptophan hydroxylase (TPH)-1, catalytic enzyme in 5-HT production, messenger RNA (mRNA) have been found in CD patients in remission who are suffering the irritable bowel syndrome (IBS)-like symptoms. Alterations in normal 5-HT signaling has also been reported in animal models of inflammatory bowel disease (IBD). Thus, the aim of the proposed research project will be to study the alterations in 5-HT signalling accompanying GI inflammatory conditions, such as IBD.

Eligibility

Min Age: 19 YearsMax Age: 85 Years

Inclusion Criteria2

Patient groups: Disease diagnosis (CD or UC),duration of disease, previous/type of treatments, duration of treatment and disease prognosis.
Healthy controls: No diagnosis of CD or UC and no diagnosis of IBS.

Exclusion Criteria2

Patient groups: Drugs that directly affect components of 5-HT signaling, any other disease or condition that may interfere with study assessments as judged by the investigator.
Healthy controls:Chronic use of any anti-inflammatory drugs, drugs that directly affect components of 5-HT signalling and any other disease or condition that may interfere with study assessments as judged by the investigator.

Interested in this trial?

Get notified about updates and connect with the research team.